ArticleExpert review of anticancer therapy2014
Hitting the bull's eye: targeting HMGA1 in cancer stem cells.
Article in Expert review of anticancer therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Differentially Methylated Regions in Human Rhombic Lip Compartments Are Enriched in Putative Active Enhancers, Human Accelerated Regions, and Medulloblastoma Copy Number Aberrations.Cerebellum (London, England) · 2026Article
- Establishment and characterization of a novel cancer stem-like cell of cholangiocarcinoma.Cancer science · 2023Article
- High Mobility Group A1 (HMGA1): Structure, Biological Function, and Therapeutic Potential.International journal of biological sciences · 2022Review
- High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer.Breast cancer research and treatment · 2020Article
- p53 balances between tissue hierarchy and anarchy.Journal of molecular cell biology · 2019Review
- Mandatory role of HMGA1 in human airway epithelial normal differentiation and post-injury regeneration.Oncotarget · 2018Article
- Transcriptional Regulation of Glucose Metabolism: The Emerging Role of the HMGA1 Chromatin Factor.Frontiers in endocrinology · 2018Review
- Robust prediction of gene regulation in colorectal cancer tissues from DNA methylation profiles.Epigenetics · 2018Article
- Crucial role of HMGA1 in the self-renewal and drug resistance of ovarian cancer stem cells.Experimental & molecular medicine · 2016Article
- The Architectural Chromatin Factor High Mobility Group A1 Enhances DNA Ligase IV Activity Influencing DNA Repair.PloS one · 2016Article
- The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.Current molecular medicine · 2016Review
- Translating Proteomic Into Functional Data: An High Mobility Group A1 (HMGA1) Proteomic Signature Has Prognostic Value in Breast Cancer.Molecular & cellular proteomics : MCP · 2016Article
- IBRUTinib: BRUTe force against bortezomib-resistant myeloma cells.Cell cycle (Georgetown, Tex.) · 2015Article
- HMGB1 in health and disease.Molecular aspects of medicine · 2014Review
- The high mobility group A1 molecular switch: turning on cancer - can we turn it off?Expert opinion on therapeutic targets · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Emerging evidence suggests that when cancer cells hijack normal stem cell properties, they acquire the ability to invade, metastasize to distant sites and evade therapy. Thus, eliminating cancer cells with stem cell properties, or cancer stem cells, is of prime importance for the successful treatment of cancer, regardless of the tissue of origin. Previous efforts to target cancer stem cells (CSCs), however, have been largely unsuccessful. Recent studies led to the discovery of a novel role for the high mobility group A1 (HMGA1) protein as a master regulator in both CSCs and normal embryonic stem cells. Here, we present exciting new work unveiling HMGA1 as a promising target for therapies directed at eradicating CSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.